According to a latest research report published by “Meticulous Research”, global clinical genomics market is expected to reach USD 879.0 million by 2023, supported by a CAGR of 17.1% during the forecast period of 2018 to 2023.
The recent developments in genomics sequencing technologies have the potential to transform the diagnosis and treatment of many diseases, specifically inherited and cancers. Medicines based on genomics are making inroads in the fields of oncology, infection, pharmacology, and rare and undiagnosed diseases. Moreover, the genetic variants in the human genome, both at the whole genome and at the exome level, provide a rational approach to diagnosis, therapy, and personalized medicine.
Here are the top 10 companies operating in the clinical genomics market –
Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Madison, New Jersey, U.S.; Quest Diagnostics Incorporated has two reportable segments such as Diagnostics Information Services and Diagnostics Solutions. The company’s diagnostic information services business segment develops and delivers diagnostic testing information and services, such as routine clinical testing, gene-based and esoteric testing, as well as anatomic pathology services, and related services.
The company has its geographic presence in the U.S., Puerto Rico, India, Ireland, and Mexico.
Eurofins Scientific SE (Luxembourg)
Eurofins Scientific SE was founded in 1987 and is headquartered in Luxembourg, Europe. The company offers a portfolio over 130,000 analytical methods and more than 150 million assays performed each year to establish the safety, identity, composition, authenticity, origin, traceability, and purity of biological substances and products, as well as carry out the human diagnostic system.
The company has its geographic presence across 39 countries in Europe, North and South America, and Asia-Pacific.
Illumina Inc. (U.S.)
Illumina, Inc. was founded in 1998 and is headquartered in San Diego, the U.S. Illumina, Inc. serves in markets such as life sciences, translational, and clinical genomics. The company operates with two reportable segments namely Core Illumina and Consolidated VIEs. The core Illumina segment comprised of products and services in the research, clinical and applied markets, and enables the adoption of a variety of genomic solutions.
Illumina, Inc. has its geographic presence in North America, Europe, Latin America, Asia-pacific, and others.
PerkinElmer, Inc. (U.S.)
PerkinElmer, Inc. was founded in 1947 and is headquartered in Waltham, Massachusetts, the U.S.; PerkinElmer, Inc. provide products, services and solutions for the diagnostics, food, environmental, industrial, life sciences research, and laboratory services markets. The company operates through its two reporting segments, Discovery & Analytical Solutions and Diagnostics.
The company has its facilities located in Europe (France, Germany, and Belgium), United States and Asia (China, India and Japan).
OPKO Health, Inc. (U.S.)
OPKO Health, Inc. was incorporated in 1991 and is headquartered in Miami, Florida; U.S. The Company has two reportable segments, namely Diagnostics and Pharmaceuticals. The Diagnostics segment primarily consists of the clinical laboratory operations through the acquisitions of Bio-Reference Laboratories, Inc.
The company has its geographic presence in the U.S., Ireland, Chile, Spain, Israel, Mexico, and other countries.
Foundation Medicine, Inc. (U.S.)
Foundation Medicine, Inc. was founded in 2009 and is headquartered in Cambridge, Massachusetts, the U.S.; Foundation Medicine, Inc. has one operating segment, which delivers molecular information about cancer products in the U.S. The company’s molecular information platform is mainly used by biopharmaceutical companies, physicians, and patients.
The company offers its products and services in the U.S. and generates majority of their revenue from this country.
Myriad Genetics, Inc. (U.S.)
Myriad Genetics, Inc. was founded in 1992 and is headquartered in Salt Lake City, Utah; Myriad Genetics, Inc., a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.
The company operates through three reportable segments, namely Research, Molecular Diagnostics, and Pharmaceutical and Clinical Services. The company offers various molecular diagnostics tests to assess the risk of developing breast and ovarian cancer.
The company has its geographic presence in the U.S., Canada, Europe, and Australia via direct sales and in China, Japan, Brazil, and other countries through their distributors.
Genomic Health, Inc, (U.S.)
Genomic Health, Inc. was founded in 2000 and is headquartered in Redwood City, California, the U.S.; Genomic Health, Inc. is a global provider of genomic-based diagnostic test that address both the overtreatment and optimal treatment of early-stage cancer, one of the greatest issues in healthcare today.
The company primarily focuses on the development and global commercialization of genomics based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.
The company has its geographic presence in the U.S. and internationally through direct sales and distributors.
Gene Security Network LLC, (U.S.) (Now Natera, Inc.)
Gene Security Network, LLC was founded in 2003 and was incorporated in 2007 and changed name to Natera, Inc. in 2012 and is headquartered in San Carlos, California, the U.S. Natera, Inc. is rapidly growing diagnostic company, providing molecular and bioinformatics technology for the management of genetic disease worldwide. The company offers various products, such as NIPT tests, carrier screening, pre-implantation genetic screening& pre-implantation genetic diagnosis, and products of conception test.
The company offers products through its direct sales force, as well as through a network of approximately 70 laboratory and distribution partners in the U.S. and Americas, excluding U.S., Europe, Middle East & Africa, and India.
NeoGenomics Inc. (U.S.)
NeoGenomics Inc. was founded in 2001 and is headquartered in Fort Myers, Florida, the U.S.; .NeoGenomics Laboratories, Inc. offers diagnostics and pharma services to pathologist, hospitals, oncologists, researchers and other clinicians.
The company mainly provides molecular and genetic testing in the U.S. with facilities in eight different laboratory locations, including Fort Myers, Florida; West Sacramento, California; Aliso Viejo, California; Irvine, California, and Houston, Texas. The company also has three smaller laboratory locations in Fresno, California; Nashville, Tennessee, and Tampa, Florida.
Popular mentions in clinical genomics market – Invitae Corporation (U.S.) Rosetta Genomics Ltd. (Israel), Centogene AG (Germany), Clinical Genomics Pty Ltd. (Australia), 23andMe, Inc. (U.S.), Iverson Genetic Diagnostics, Inc. (U.S.), Veritas Genetics (U.S.), Gene by Gene, Ltd., (U.S.), GenomeDx Biosciences, Inc. (Canada), MedGenome (India), Strand Life Sciences Pvt. Ltd. (India), Beijing Genomic Institute (China), Retrogen Inc. (U.S.), Personalis Inc, (U.S.), and PathGroup (U.S.) .
To get a sample report on clinical genomics market, please visit below link: